US 2005/0033017 A1 · Soluble rage protein

Abstract

The object of this invention is to elucidate the factors involved in the regulation of AGE (advanced glycation endproducts, which are produced in a living body accompanied with diabetes and aging) and RAGE (the receptor for AGE), in order to facilitate investigation on the biological activities, physiological phenomenon and diseases related to AGE and RAGE. Plural molecular species are known to exist for RAGE, and among such molecular species, soluble RAGE exhibits the activity to modulate interaction between AGE and transmembrane-type RAGE. Using this soluble RAGE or a nucleic acid encoding it, the soluble RAGE can be measured, in addition, investigation on various physiological phenomenon, biological activities, and diseases related to interaction between AGE and RAGE can be performed to facilitate development a medicine having further efficacy.

Claims27

Dependent claims

(Canceled)

A nucleic acid having a base sequence coding for the polypeptide according to claim 23.

A polypeptide described in any one of the following (1) to (4) or a salt thereof:

(1) (i) a polypeptide having at least 60% homology with the amino acid sequence described in the ID No. 2 of the sequence listing, and;
(ii) (a) a polypeptide deleted of the transmembrane domain of the membrane-bound type RAGE protein and having a serial amino acid sequence comprising at least 1 to 16 amino acid residues out of Glu332 to Met347 of the amino acid sequence described in the SEQ ID No. 2 of the sequence listing at its C terminal;
(b) a polypeptide having a serial amino acid sequence comprising at least 1 to 117 amino acid residues out of Met1 to Val117 at the N terminal of the amino acid sequence described in the SEQ ID No. 2 of the sequence listing;
deleted with the transmembrane domain of the membrane-bound type RAGE protein;
and having a serial amino acid sequence comprising at least 1 to 16 amino acid residues out of Glu332 to Met347 of the amino acid sequence described in the SEQ ID No. 2 of the sequence listing at its C terminal;
(c) a polypeptide having a serial amino acid sequence comprising at least 1 to 1 17 amino acid residues out of a serial amino acid sequence comprising 1 to 117 amino acid residues at the N terminal of the amino acid sequence of the membrane-bound type RAGE polypeptide, and having a serial amino acid sequence comprising at least 1 to 16 amino acid residues out of Glu332 to Met347 of the amino acid sequence described in the SEQ ID No. 2 of the sequence listing at its C terminal;
and
(d) a polypeptide having amino acid sequence as described in the SEQ ID No.2 of the sequence listing, or a polypeptide exhibiting substantially equivalent biological activity with the polypeptide described in the SEQ ID No. 2 of the sequence listing;
(2) a polypeptide comprising at least 1 to 16 amino acid residues out of Glu332 to Met347 of the amino acid sequence described in the SEQ ID No. 2 of the sequence listing;
and comprising the following part of the amino acid sequence described in the SEQ ID No.2 of the sequence listing or a salt thereof:
(i) a serial amino acid sequence comprising at least 5 to 115 amino acid residues;
(ii) a serial amino acid sequence comprising at least 116 to 230 amino acid residues;
(iii) a serial amino acid sequence comprising at least 231 to 347 amino acid residues;
(iv) a serial amino acid sequence comprising at least one amino acid residue out of the 1st to 117th amino acid residues;
(v) a serial amino acid sequence comprising at least one amino acid residue out of the 332nd to 347th amino acid residues;
(vi) an amino acid sequence comprising the 19th to 347th amino acid residues;
(vii) a serial amino acid sequence comprising the 1st to 347th amino acid residues;
and
(viii) a polypeptide having an amino acid sequence substantially equivalent to any one of the above-mentioned polypeptides;
(3) a polypeptide selected from the polypeptides previously described in (1) or (2), which has an activity toward diseases caused by alteration in the interaction between AGE and its receptor, the expression of the soluble RAGE and/or the activity to capture AGE, or a salt thereof;
and
(4) a partial peptide or a salt of a polypeptide selected from the polypeptides as described in (1), (2) and (3).

19 more elements

Dependencies are inferred from the claim text.

Soluble rage protein

Life of this patent

Soluble rage protein

Life of this patent

Abstract

Claims27